**AASLD 2023 Practice Guidelines on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease**

By: Nidah S. Khakoo, M.D.

NAFLD is a spectrum of disease, defined as a population in which ≥5% of hepatocytes display macrovascular steatosis, in the absence of alternative causes in individuals who drink little/no alcohol.

- Includes *nonalcoholic fatty, nonalcoholic steatohepatitis* (inflammation and cellular injury with or without fibrosis) and *cirrhosis* (characterized by bands of fibrous septa and cirrhotic nodules).
- Prevalence in adults is approximately 25-30%, but often remains undiagnosed.
- Rates of fibrosis progression and decompensation vary depending on baseline disease severity, genetic, environmental, and comorbid diseases.

**Guidance Statements (GS) 1 - 7: Comorbid Conditions and Alcohol Consumption**

**Comorbid conditions:** Type II Diabetes Mellitus (DM2), hypertension (HTN), dyslipidemia (HLD), cardiovascular disease (CVD)

- **CVD** → statins recommended, including in compensated cirrhosis (careful monitoring in decompensated cirrhosis)
- **HLD** → lifestyle changes + omega-3 fatty acids, icosapent ethyl, or fibrates recommended.
- **DM2** → screen and monitor for advanced fibrosis
- **All patients with clinically significant fibrosis (≥F2)** → complete alcohol abstinence.

**RS 8: No need to routinely measure testosterone levels in NAFLD patients.**

- ↑ rates of NAFLD in hypothyroidism, hypogonadism, growth hormone deficiency, and polycystic ovarian syndrome.
- ↑ rates of NAFLD in androgen deficiency; however, no evidence to measure testosterone levels.

**GSs 9 – 12: Screening for Advanced Fibrosis**

- **Avoid** general population-based screening.
- All patients with NAFLD + obesity or other metabolic factors → **primary risk assessment with FIB-4**
  - Repeat @ 1-2 year intervals
- All high risk individuals → **screen for advanced fibrosis**
  - High risk: DM2, obesity, family history of cirrhosis

**GS 13: Patients with NASH cirrhosis are at the highest risk for liver-related decompensation and require routine surveillance.**

**GS 14: If advanced NASH with a discordant NIT → referral to specialist for management and evaluation.**

- Alternative methods = VCTE (e.g., FibroScan), MRE, ELF.
  - Can help predict an ↑ risk of hepatic decompensation & mortality.

**GSs 15 – 16: If advanced NASH fibrosis:**

- Aminotransferase levels may be normal in advanced stages, so not a reliable marker
- 1st degree relatives should be counseled re: ↑ risk and offered screening for NAFLD

**CAP = controlled attenuation parameter**

**MRE = magnetic resonance elastography**

**NIT = non-invasive testing**

**VCTE = vibration-controlled elastography**

**GS 19: If FIB-4 ≥ 1.3, alternative NITs should be used to exclude advanced fibrosis.***

*In age >65, FIB-4 ≥ 2.

**GS 17 – 18: Ultrasound (US) is not recommended to diagnose NAFLD.**

- US lacks sensitivity & only provides subjective quantification of steatosis.
- CAP with VCTE → superior point-of-care technique to quantify steatosis

**GSs 17 – 18: Ultrasound (US) is not recommended to diagnose NAFLD.**

- US lacks sensitivity & only provides subjective quantification of steatosis.
- CAP with VCTE → superior point-of-care technique to quantify steatosis

GS 20 - 21: Patients with NAFLD who are overweight/obese should 1) be on a diet that leads to calorie deficit and 2) ↑ exercise as much as possible.

- Weight loss improves steatosis, NASH, and fibrosis in a **dose-dependent manner**.
- 3 cups of coffee daily = less advanced liver disease.

GS 22: Bariatric surgery should be considered an option for all patients that meet criteria in patients w/o cirrhosis.*

- Resolves NAFLD in majority of patients and ↓ mortality from CVD and malignancy.
- *In patients with decompensated cirrhosis, bariatric surgery = **absolute contraindication**.

GSs 23 – 28: In those with NASH + DM2, consider Semaglutide and Pioglitazone. If w/o DM2, consider Vitamin E.**

- These may improve NASH, but do **not have** an antifibrotic effect.
- Metformin, UDCA, DPP-4, statins, and silymarin do **not have** histological benefit and should not be used.

GS 29: ALT improvement or reduction in fat by imaging techniques can be used as a histological marker of improvement.

- ALT normalization can predict NASH resolution.
- Histological improvement can also be tracked by NITs (i.e., FIB-4, FAST, ELF, VCTE).